Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.
about
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjectsReview of management of type 2 diabetes mellitus.SEDDS of gliclazide: Preparation and characterization by in-vitro, ex-vivo and in-vivo techniques.Development, optimization, and anti-diabetic activity of gliclazide-loaded alginate-methyl cellulose mucoadhesive microcapsulesPopulation PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetesApplying the Taguchi design for optimized formulation of sustained release gliclazide chitosan beads: an in vitro/in vivo studyInfluence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal modelsEffects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study.Development and validation of LC/MS/MS method for the simultaneous determination of montelukast, gliclazide, and nifedipine and its application to a pharmacokinetic study.Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.Pharmacokinetics and pharmacodynamics of gliclazide from immediate and modified release formulation tablets in rats.Influence of quercetin on the interaction of gliclazide with human serum albumin - spectroscopic and docking approaches.Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics.Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat.Controlled porosity solubility modulated osmotic pump tablets of gliclazide.Physicochemical properties of solid dispersions of gliclazide in polyvinylpyrrolidone K90.Physicochemical investigations and stability studies of amorphous gliclazide.Gliclazide microcrystals prepared by two methods of in situ micronization: pharmacokinetic studies in diabetic and normal rats.Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000.Bioequivalence study of modified-release gliclazide tablets in healthy volunteers.Physicochemical characterization of gliclazide-macrogol solid dispersion and tablets based on optimized dispersion.Preparation and crystallographic analysis of gliclazide polymorphs.Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers.Bioequivalence evaluation of two brands of gliclazide 80 mg tablets (Glyzide & Diamicron)--in healthy human volunteers.In vitro evaluation and in vivo performance of lyophilized gliclazide.Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes.High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect.Multicomponent crystals of gliclazide and tromethamine: preparation, physico-chemical, and pharmaceutical characterization.Liquid Chromatography‐Electrospray Ionization Mass Spectrometric Method for Determination of Gliclazide in Human Plasma
P2860
Q24564755-6CA32361-61BC-40A3-9A37-9474A26A35E0Q33536960-A176F7C4-587B-4FF7-BFF0-07636FADC376Q35232731-C40BA315-9563-4A49-973B-B33B729D3365Q35577235-80E42F6E-7D2E-4433-BB04-7DE4F2CEF835Q35846713-302B2050-4991-4708-85DB-F040238B7D2EQ36055097-915F7C60-E362-4173-B660-5CF41E9C42EAQ37146176-2D578792-CC96-40AE-BB24-7FC8022AEA2AQ37395532-7F4CFF6E-099B-4FB2-AD24-DFAD141D19A8Q37663519-BB67A947-8B54-4804-9487-40F050A93F7FQ37699725-230326A4-333D-4ACF-99CD-09B4895B45E4Q38541323-3C44A2DF-BB26-4D14-AB1C-456EC9F2FABCQ38640667-3E6A1E8D-46EE-4FEC-85DD-EDF8096BD91CQ38781272-002DBC5E-3F27-4005-9ABB-E0B20F662E10Q39351329-F8AFE69D-CDED-40BC-872C-B61AFAB2293EQ40509847-3ED2FF38-43D5-4E65-A0BA-274A5E46A332Q41110266-6FBFA4A0-59CA-4632-ABF4-0AF2CF9611D6Q41973412-94DCABD9-61DA-4384-92B1-FF5E924F2095Q41988346-E8603F4B-ACE5-4053-8615-3705F1BCCA2CQ41988871-43CA4BE2-1A27-42CA-976D-F0DAD51FC14CQ41989600-10F8F8BD-733C-4868-96EB-6FD838B48074Q42641023-91266DC5-DE88-44DC-880D-6585DF56D52FQ43145008-3D1E5222-3920-4476-8F34-349AA61640D0Q43182734-A34B945A-19DE-4A82-A7C3-D3BE0C1E583EQ43996960-ECDBF0DA-6096-4033-8892-EEABC9BBAB2FQ44063005-66E31830-001A-49DF-92B7-2614CB48A090Q46573834-C8CB5E73-495C-48EE-ACFF-87C3453377C2Q47404089-DDEE63A0-7971-4E28-8A94-6764556BE0B7Q48089000-00915D9C-D30A-4D64-9878-982CF48C86CBQ49687596-DCD98989-6657-4086-AEB2-DC57D6EAA581Q58129692-B8F30C46-C9F2-43FD-8983-64A920ACFBF2
P2860
Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Gliclazide. An update of its p ...... n-dependent diabetes mellitus.
@en
type
label
Gliclazide. An update of its p ...... n-dependent diabetes mellitus.
@en
prefLabel
Gliclazide. An update of its p ...... n-dependent diabetes mellitus.
@en
P1433
P1476
Gliclazide. An update of its p ...... n-dependent diabetes mellitus.
@en
P2093
K J Palmer
P304
P356
10.2165/00003495-199346010-00007
P577
1993-07-01T00:00:00Z
P6179
1053052042